INVESTOR ALERT: Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead the Tempus AI Class Action Lawsuit - TEM
Robbins Geller Rudman & Dowd LLP has set a deadline of August 12, 2025, for investors to seek appointment as lead plaintiff in the Tempus AI, Inc. common stock case. The Class Period for the lawsuit is between August 6, 2024, and May 27, 2025. Investors who purchased TEM stock during this period may be eligible to participate in the legal action. The announcement was made on June 18, 2025, in San Diego. It is advisable for affected investors to take necessary steps before the deadline.
Tempus AI Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024, and May 27, 2025, inclusive (the "Class Period"), have until August 12, 2025, to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI and certain of Tempus AI's top executives with violations of the Securities Exchange Act of 1934.
Tempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence, including generative AI. The Tempus AI class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose several key points:
- Tempus AI inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded.
- The credibility and substance of Tempus AI's joint venture with SoftBank Group Corporation was at risk because it gave the appearance of "round-tripping" capital to create revenue for Tempus AI.
- Tempus AI-acquired Ambry Genetics Corporation had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability.
- AstraZeneca PLC had reduced its financial commitments to Tempus AI through a questionable "pass-through payment" via a joint agreement between it, Tempus AI, and Pathos AI, Inc.
- The above issues revealed weakness in core operations and revenue prospects.
The Tempus AI class action lawsuit further alleges that on May 28, 2025, Spruce Point Capital Management, LLC issued a research report on Tempus AI that raised numerous red flags over Tempus AI's management, operations, and financial reporting. On this news, the price of Tempus AI stock fell more than 19%, according to the complaint.
The Lead Plaintiff Process
The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Tempus AI common stock during the Class Period to seek appointment as lead plaintiff in the Tempus AI class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Tempus AI class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Tempus AI class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Tempus AI class action lawsuit.
About Robbins Geller
Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history. Please visit the following page for more information: https://www.rgrdlaw.com/services-litigation-securities-fraud.html
Contact: Robbins Geller Rudman & Dowd LLP
J.C. Sanchez, Jennifer N. Caringal
655 W. Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
[email protected]